CoChat
Sign Up
Cited by 134Biochemical effects in animalsTrace Elements in HealthAlzheimer's disease research and treatments

Zinc, Carnosine, and Neurodegenerative Diseases

Open access
Kawahara, Masahiro, Tanaka, Ken-ichiro, Kato-Negishi, Midori·2018·Nutrients
DOI 10.3390/nu10020147PMC PMC5852723
Open this paper in CoChat — free accountOpen PDF

Abstract

Zinc (Zn) is abundantly present in the brain, and accumulates in the synaptic vesicles. Synaptic Zn is released with neuronal excitation, and plays essential roles in learning and memory. Increasing evidence suggests that the disruption of Zn homeostasis is involved in various neurodegenerative diseases including Alzheimer’s disease, a vascular type of dementia, and prion diseases. Our and other numerous studies suggest that carnosine (β-alanyl histidine) is protective against these neurodegenerative diseases. Carnosine is an endogenous dipeptide abundantly present in the skeletal muscles and in the brain, and has numerous beneficial effects such as antioxidant, metal chelating, anti-crosslinking, and anti-glycation activities. The complex of carnosine and Zn, termed polaprezinc, is widely used for Zn supplementation therapy and for the treatment of ulcers. Here, we review the link between Zn and these neurodegenerative diseases, and focus on the neuroprotective effects of carnosine. We also discuss the carnosine level in various foodstuffs and beneficial effects of dietary supplementation of carnosine.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nu10020147

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Zinc supplementation has been considered for restoring synaptic function, though clinical evidence remains mixed.

    “Zinc supplementation, carefully titrated, has also been considered as a means of restoring synaptic function, though clinical evidence remains mixed [114].”

    From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [114]

    The Introduction (page unavailable) says zinc supplementation is used to treat deficiency and certain non-neurological conditions, while the section 'Roles of Zinc in the Brain' describes zinc’s role at synapses. Neither passage presents carefully titrated supplementation as a way to restore synaptic function, and the paper does not report mixed clinical evidence for that use. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 113

  1. [1]Ackland M.L. Michalczyk A.A. Zinc and infant nutrition Arch. Biochem. Biophys. 2016 611 51 57 10.1016/j.abb.2016.06.011 27317042 · DOI
  2. [2]Wessels I. Maywald M. Rink L. Zinc as a gatekeeper of immune function Nutrients 2017 9 1286 10.3390/nu9121286 29186856 PMC5748737 · DOI
  3. [3]Hojyo S. Fukada T. Roles of Zinc signaling in the immune system J. Immunol. Res. 2016 2016 10.1155/2016/6762343 27872866 PMC5107842 · DOI
  4. [4]Andreini C. Banci L. Bertini I. Rosato A. Counting the zinc-proteins encoded in the human genome J. Proteome Res. 2006 5 196 201 10.1021/pr050361j 16396512 · DOI · Paper page
  5. [5]Prasad A.S. Impact of the discovery of human zinc deficiency on health J. Am. Coll. Nutr. 2009 28 257 265 10.1080/07315724.2009.10719780 20150599 · DOI
  6. [6]Hambidge M. Human zinc deficiency J. Nutr. 2000 130 1344S 1349S 10.1093/jn/130.5.1344S 10801941 · DOI
  7. [7]Takeda A. Tamano H. Subclinical zinc deficiency impairs human brain function J. Trace Elem. Med. Biol. 2012 26 70 73 22673824
  8. [8]Doboszewska U. Wlaź P. Nowak G. Radziwoń-Zaleska M. Cui R. Młyniec K. Zinc in the monoaminergic theory of depression: Its relationship to neural plasticity Neural Plast. 2017 2017 10.1155/2017/3682752 28299207 PMC5337390 · DOI
  9. [9]Udechukwu M.C. Collins S.A. Udenigwe C.C. Prospects of enhancing dietary zinc bioavailability with food-derived zinc-chelating peptides Food Funct. 2016 7 4137 4144 10.1039/C6FO00706F 27713952 · DOI
  10. [10]Yasuda H. Tsutsui T. Infants and elderlies are susceptible to zinc deficiency Sci. Rep. 2016 6 21850 10.1038/srep21850 26912464 PMC4766432 · DOI
  11. [12]Heintschel M. Heuberger R. The potential role of zinc supplementation on pressure injury healing in older adults: A review of the literature Wounds 2017 29 56 61 28272014
  12. [13]Awotiwon A.A. Oduwole O. Sinha A. Okwundu C.I. Zinc supplementation for the treatment of measles in children Cochrane Database Syst. Rev. 2017 6 CD011177 10.1002/14651858.CD011177.pub3 28631310 PMC6481361 · DOI
  13. [14]Heyneman C.A. Zinc deficiency and taste disorders Ann. Pharmacother. 1996 30 186 187 10.1177/106002809603000215 8835055 · DOI
  14. [15]Ikeda M. Aiba T. Ikui A. Inokuchi A. Kurono Y. Sakagami M. Takeda N. Tomita H. Taste disorders: A survey of the examination methods and treatments used in Japan Acta Otolaryngol. 2009 129 1115 1120 10.1080/00016480510040173 16353402 · DOI
  15. [16]Matsukura T. Tanaka H. Applicability of zinc complex of l-carnosine for medical use Biochemistry 2000 65 817 823 10951100
  16. [17]Suzuki H. Mori M. Seto K. Miyazawa M. Kai A. Suematsu M. Yoneta T. Miura S. Ishii H. Polaprezinc attenuates the Helicobacter pylori-induced gastric mucosal leucocyte activation in Mongolian gerbils—A study using intravital videomicroscopy Aliment. Pharmacol. Ther. 2001 15 715 725 10.1046/j.1365-2036.2001.00960.x 11328267 · DOI
  17. [18]Boldyrev A.A. Aldini G. Derave W. Physiology and pathophysiology of carnosine Physiol. Rev. 2013 93 1803 1845 10.1152/physrev.00039.2012 24137022 · DOI
  18. [19]Hipkiss A.R. On the relationship between energy metabolism, proteostasis, aging and Parkinson’s disease: Possible causative role of methylglyoxal and alleviative potential of carnosine Aging Dis. 2017 8 334 345 10.14336/AD.2016.1030 28580188 PMC5440112 · DOI
  19. [20]Corona C. Frazzini V. Silvestri E. Lattanzio R. La Sorda R. Piantelli M. Canzoniero L.M. Ciavardelli D. Rizzarelli E. Sensi S.L. Effects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xTg-AD mice PLoS ONE 2011 6 e17971 10.1371/journal.pone.0017971 21423579 PMC3058055 · DOI
  20. [21]Mizuno D. Kawahara M. Carnosine: A possible drug for vascular dementia J. Vasc. Med. Surg. 2014 2 3 10.4172/2329-6925.1000146 · DOI
  21. [22]Kawahara M. Koyama H. Nagata T. Sadakane Y. Zinc, copper, and carnosine attenuate neurotoxicity of prion fragment PrP106-126 Metallomics 2011 3 726 734 10.1039/c1mt00015b 21442127 · DOI
  22. [23]Chez M.G. Buchanan C.P. Aimonovitch M.C. Becker M. Schaefer K. Black C. Komen J. Double-blind, placebo-controlled study of l-carnosine supplementation in children with autistic spectrum disorders J. Child Neurol. 2002 17 833 837 10.1177/08830738020170111501 12585724 · DOI
  23. [24]Baraniuk J.N. El-Amin S. Corey R. Rayhan R. Timbol C. Carnosine treatment for gulf war illness: A randomized controlled trial Glob. J. Health Sci. 2013 5 69 81 10.5539/gjhs.v5n3p69 23618477 PMC4209301 · DOI
  24. [25]Rokicki J. Li L. Imabayashi E. Kaneko J. Hisatsune T. Matsuda H. Daily carnosine and anserine supplementation alters verbal episodic memory and resting state network connectivity in healthy elderly adults Front. Aging Neurosci. 2015 7 219 10.3389/fnagi.2015.00219 26640437 PMC4661275 · DOI
  25. [26]Frederickson C.J. Suh S.W. Silva D. Frederickson C.J. Thompson R.B. Importance of zinc in the central nervous system: The zinc-containing neuron J. Nutr. 2000 130 1471S 1483S 10.1093/jn/130.5.1471S 10801962 · DOI
  26. [27]Frederickson C.J. Klitenick M.A. Manton W.I. Kirkpatrick J.B. Cytoarchitectonic distribution of zinc in the hippocampus of man and the rat Brain Res. 1983 27 335 339 10.1016/0006-8993(83)90858-2 6616240 · DOI
  27. [28]Sensi S.L. Paoletti P. Koh J.Y. Aizenman E. Bush A.I. Hershfinkel M. The neurophysiology and pathology of brain zinc J. Neurosci. 2011 31 16076 16085 10.1523/JNEUROSCI.3454-11.2011 22072659 PMC3223736 · DOI
  28. [29]Ueno S. Tsukamoto M. Hirano T. Kikuchi K. Yamada M.K. Nishiyama N. Nagano T. Matsuki N. Ikegaya Y. Mossy fiber Zn2+ spillover modulates heterosynaptic N-methyl-d-aspartate receptor activity in hippocampal CA3 circuits J. Cell Biol. 2002 158 215 220 10.1083/jcb.200204066 12119362 PMC2173116 · DOI
  29. [30]Takeda A. Nakamura M. Fujii H. Tamano H. Synaptic Zn2+ homeostasis and its significance Metallomics 2013 5 417 423 10.1039/c3mt20269k 23423555 · DOI
  30. [31]Wang X. Sommer F.T. Hirsch J.A. Inhibitory circuits for visual processing in thalamus Curr. Opin. Neurobiol. 2011 21 726 733 10.1016/j.conb.2011.06.004 21752634 PMC3767471 · DOI
  31. [32]D’Ambrosi N. Rossi L. Copper at synapse: Release, binding and modulation of neurotransmission Neurochem. Int. 2015 90 36 45 10.1016/j.neuint.2015.07.006 26187063 · DOI
  32. [33]Schikorski T. Stevens C.F. Quantitative ultrastructural analysis of hippocampal excitatory synapses J. Neurosci. 1997 17 5858 5867 9221783 PMC6573206
  33. [34]Vogt K. Mellor J. Tong G. Nicoll R. The actions of synaptically released zinc at hippocampal mossy fiber synapses Neuron 2000 26 187 196 10.1016/S0896-6273(00)81149-6 10798403 · DOI
  34. [35]Hopt A. Korte S. Fink H. Panne U. Niessner R. Jahn R. Herms J. Methods for studying synaptosomal copper release J. Neurosci. Methods 2003 128 159 172 10.1016/S0165-0270(03)00173-0 12948559 · DOI
  35. [36]Bauer K. Carnosine and homocarnosine, the forgotten, enigmatic peptides of the brain Neurochem. Res. 2005 30 1339 1345 10.1007/s11064-005-8806-z 16341596 · DOI
  36. [37]Bolognin S. Cozzi B. Zambenedetti P. Zatta P. Metallothioneins and the central nervous system: From a deregulation in neurodegenerative diseases to the development of new therapeutic approaches J. Alzheimers Dis. 2014 41 29 42 24577478
  37. [38]Fukada T. Kambe T. Molecular and genetic features of zinc transporters in physiology and pathogenesis Metallomics 2011 3 662 674 10.1039/c1mt00011j 21566827 · DOI
  38. [39]Bin B.H. Fukada T. Hosaka T. Yamasaki S. Ohashi W. Hojyo S. Miyai T. Nishida K. Yokoyama S. Hirano T. Biochemical characterization of human ZIP13 protein: A homo-dimerized zinc transporter involved in the spondylocheiro dysplastic ehlers-danlos syndrome J. Biol. Chem. 2011 286 40255 40265 10.1074/jbc.M111.256784 21917916 PMC3220551 · DOI
  39. [40]Kawahara M. Mizuno D. Koyama H. Konoha K. Ohkawara S. Sadakane Y. Disruption of zinc homeostasis and the pathogenesis of senile dementia Metallomics 2013 6 209 219 10.1039/C3MT00257H 24247360 · DOI
  40. [41]Mizuno D. Koyama H. Ohkawara S. Sadakane Y. Kawahara M. Involvement of trace elements in the pathogenesis of prion diseases Curr. Pharam. Biotechnol. 2014 15 1049 1057 10.2174/1389201015666141103020625 25373386 · DOI
  41. [42]Sirangelo I. Iannuzzi C. The role of metal binding in the amyotrophic lateral sclerosis-related aggregation of copper-zinc superoxide dismutase Molecules 2017 22 1429 10.3390/molecules22091429 28850080 PMC6151412 · DOI
  42. [43]Kawahara M. Kato-Negishi M. Tanaka K. Cross talk between neurometals and amyloidogenic proteins at the synapse and the pathogenesis of neurodegenerative diseases Metallomics 2017 9 619 633 10.1039/C7MT00046D 28516990 · DOI · Paper page
  43. [44]Selkoe D.J. The molecular pathology of Alzheimer’s disease Neuron 1991 6 487 498 10.1016/0896-6273(91)90052-2 1673054 · DOI · Paper page
  44. [45]Hardy J.A. Higgins G.A. Alzheimer’s disease: The amyloid cascade hypothesis Science 1992 256 184 185 10.1126/science.1566067 1566067 · DOI · Paper page
  45. [46]Wirths O. Multhaup G. Bayer T.A. A modified β-amyloid hypothesis: Intraneuronal accumulation of the β-amyloid peptide—The first step of a fatal cascade J. Neurochem. 2004 91 513 520 10.1111/j.1471-4159.2004.02737.x 15485483 · DOI
  46. [47]Goate A. Chartier-Harlin M.C. Mullan M. Brown J. Crawford F. Fidani L. Giuffra L. Haynes A. Irving N. James L. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease Nature 1991 349 704 706 10.1038/349704a0 1671712 · DOI · Paper page
  47. [48]Yankner B.A. Duffy L.K. Kirschner D.A. Neurotropic and neurotoxic effects of amyloid β protein: Reversal by tachykinin neuropeptides Nature 1990 250 279 282 2218531
  48. [49]Kawahara M. Negishi-Kato M. Sadakane Y. Calcium dyshomeostasis and neurotoxicity of Alzheimer’s beta-amyloid protein Expert Rev. Neurother. 2009 9 681 693 10.1586/ern.09.28 19402778 · DOI
  49. [50]Pike C.J. Walencewicz A.J. Glabe C.G. Cotman C.W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity Brain Res. 1991 563 311 314 10.1016/0006-8993(91)91553-D 1786545 · DOI
  50. [51]Fukuyama R. Mizuno T. Mori S. Nakajima K. Fushiki S. Yanagisawa K. Age-dependent change in the levels of Aβ40 and Aβ42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Aβ42 to Aβ40 level in cerebrospinal fluid from Alzheimer’s disease patients Eur. Neurol. 2000 43 155 160 10.1159/000008156 10765056 · DOI
  51. [52]Kawahara M. Role of calcium dyshomeostasis via amyloid channels in the pathogenesis of Alzheimer’s disease Curr. Pharm. Des. 2010 16 2779 2789 10.2174/138161210793176545 20698821 · DOI
  52. [53]Dyrks T. Dyrks E. Masters C.L. Beyreuther K. Amyloidogenicity of rodent and human βA4 sequences FEBS Lett. 1993 324 231 236 10.1016/0014-5793(93)81399-K 8508926 · DOI
  53. [56]Solomonov I. Korkotian E. Born B. Feldman Y. Bitler A. Rahimi F. Li H. Bitan G. Sagi I. Zn2+-Aβ40 complexes form metastable quasi-spherical oligomers that are cytotoxic to cultured hippocampal neurons J. Biol. Chem. 2012 287 20555 20564 10.1074/jbc.M112.344036 22528492 PMC3370240 · DOI
  54. [57]Chen W.T. Liao Y.H. Yu H.M. Cheng I.H. Chen Y.R. Distinct effects of Zn2+, Cu2+, Fe3+, and Al3+ on amyloid-beta stability, oligomerization, and aggregation: Amyloid-β destabilization promotes annular protofibril formation J. Biol. Chem. 2011 286 9646 9656 10.1074/jbc.M110.177246 21216965 PMC3059000 · DOI
  55. [58]Bolognin S. Zatta P. Lorenzetto E. Valenti M.T. Buffelli M. β-Amyloid-aluminum complex alters cytoskeletal stability and increases ROS production in cortical neurons Neurochem. Int. 2013 62 566 574 10.1016/j.neuint.2013.02.008 23416043 · DOI
  56. [60]Kawahara M. Kato M. Kuroda Y. Effects of aluminum on the neurotoxicity of primary cultured neurons and on the aggregation of β-amyloid protein Brain Res. Bull. 2001 55 211 217 10.1016/S0361-9230(01)00475-0 11470317 · DOI
  57. [61]Small D.H. Mok S.S. Bornstein J.C. Alzheimer’s disease and Aβ toxicity: From top to bottom Nat. Rev. Neurosci. 2001 2 595 598 10.1038/35086072 11484003 · DOI
  58. [62]Demuro A. Parker I. Stutzmann G.E. Calcium signaling and amyloid toxicity in Alzheimer disease J. Biol. Chem. 2010 285 12463 12468 10.1074/jbc.R109.080895 20212036 PMC2857063 · DOI
  59. [63]Arispe N. Rojas E. Pollard H.B. Alzheimer disease amyloid β protein forms calcium channels in bilayer membranes: Blockade by tromethamine and aluminum Proc. Natl. Acad. Sci. USA 1993 90 567 571 10.1073/pnas.90.2.567 8380642 PMC45704 · DOI
  60. [64]Kawahara M. Arispe N. Kuroda Y. Rojas E. Alzheimer’s disease amyloid β-protein forms Zn2+-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons Biophys. J. 1997 73 67 75 10.1016/S0006-3495(97)78048-2 9199772 PMC1180909 · DOI
  61. [65]Kawahara M. Arispe N. Kuroda Y. Rojas E. Alzheimer’s β-amyloid, human islet amylin and prion protein fragment evoke intracellular free-calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell-line J. Biol. Chem. 2000 275 14077 14083 10.1074/jbc.275.19.14077 10799482 · DOI
  62. [66]Kawahara M. Ohtsuka I. Yokoyama S. Kato-Negishi M. Sadakane Y. Membrane incorporation, channel formation, and disruption of calcium homeostasis by Alzheimer’s β-amyloid protein Int. J. Alzheimers Dis. 2011 2011 10.4061/2011/304583 PMC3087492 21547225 · DOI
  63. [67]Sepulveda F.J. Parodi J. Peoples R.W. Opazo C. Aguayo L.G. Synaptotoxicity of Alzheimer β amyloid can be explained by its membrane perforating property PLoS ONE 2010 27 e11820 10.1371/journal.pone.0011820 20676404 PMC2910737 · DOI
  64. [68]Arispe N. Pollard H.B. Rojas E. Zn2+ interactions with Alzheimer’s amyloid β protein calcium channels Proc. Natl. Acad. Sci. USA 1996 93 1710 1715 10.1073/pnas.93.4.1710 8643694 PMC40007 · DOI
  65. [69]Lin H. Bhatia R. Lal R. Amyloid β protein forms ion channels: Implications for Alzheimer’s disease pathophysiology FASEB J. 2001 15 2433 2444 10.1096/fj.01-0377com 11689468 · DOI
  66. [70]Kepp K.P. Alzheimer’s disease due to loss of function: A new synthesis of the available data Prog. Neurobiol. 2016 143 36 60 10.1016/j.pneurobio.2016.06.004 27327400 · DOI
  67. [71]Wild K. August A. Pietrzik C.U. Kins S. Structure and synaptic function of metal binding to the amyloid precursor protein and its proteolytic fragments Front. Mol. Neurosci. 2017 10 21 10.3389/fnmol.2017.00021 28197076 PMC5281630 · DOI
  68. [72]Rogers J.T. Randall J.D. Cahill C.M. Eder P.S. Huang X. Gunshin H. Leiter L. McPhee J. Sarang S.S. Utsuki T. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer’s amyloid precursor protein transcript J. Biol. Chem. 2002 277 45518 45528 10.1074/jbc.M207435200 12198135 · DOI · Paper page
  69. [73]Wong B.X. Tsatsanis A. Lim L.Q. Adlard P.A. Bush A.I. Duce J.A. β-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin PLoS ONE 2014 9 e114174 10.1371/journal.pone.0114174 25464026 PMC4252103 · DOI
  70. [74]Soto C. Sigurdsson E.M. Morelli L. Kumar R.A. Castaño E.M. Frangione B. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer’s therapy Nat. Med. 1998 4 822 826 10.1038/nm0798-822 9662374 · DOI
  71. [75]Babizhayev M.A. Antioxidant activity of l-carnosine, a natural histidine-containing dipeptide in crystalline lens Biochim. Biophys. Acta 1989 1004 363 371 10.1016/0005-2760(89)90085-4 2758030 · DOI
  72. [76]Dubois V.D. Bastawrous A. N-acetylcarnosine (NAC) drops for age-related cataract Cochrane Database Syst. Rev. 2017 2 CD009493 10.1002/14651858.CD009493.pub2 28245346 PMC6464029 · DOI
  73. [77]Aloisi A. Barca A. Romano A. Guerrieri S. Storelli C. Rinaldi R. Verri T. Anti-aggregating effect of the naturally occurring dipeptide carnosine on Aβ1-42 fibril formation PLoS ONE 2013 8 e68159 10.1371/journal.pone.0068159 23844165 PMC3700870 · DOI
  74. [78]Attanasio F. Convertino M. Magno A. Caflisch A. Corazza A. Haridas H. Esposito G. Cataldo S. Pignataro B. Milardi D. Carnosine inhibits Aβ42 aggregation by perturbing the H-bond network in and around the central hydrophobic cluster ChemBioChem 2013 14 583 592 10.1002/cbic.201200704 23440928 · DOI
  75. [79]Fonteh A.N. Harrington R.J. Tsai A. Liao P. Harrington M.G. Free amino acid and dipeptide changes in the body fluids from Alzheimer’s disease subjects Amino Acids 2007 32 213 224 10.1007/s00726-006-0409-8 17031479 · DOI
  76. [80]Choi D.W. Calcium: Still center-stage in hypoxic-ischemic neuronal death Trends Neurosci. 1995 18 58 60 10.1016/0166-2236(95)80018-W 7537408 · DOI
  77. [81]Choi D.W. Koh J.Y. Zinc and brain injury Annu. Rev. Neurosci. 1998 21 347 375 10.1146/annurev.neuro.21.1.347 9530500 · DOI
  78. [82]Weiss J.H. Sensi S.L. Koh J.Y. Zn2+: A novel ionic mediator of neural injury in brain disease Trends Pharmacol. Sci. 2000 21 395 401 10.1016/S0165-6147(00)01541-8 11050320 · DOI
  79. [83]Koh J.Y. Suh S.W. Gwag B.J. He Y.Y. Hsu C.Y. Choi D.W. The role of zinc in selective neuronal death after transient global cerebral ischemia Science 1996 272 1013 1016 10.1126/science.272.5264.1013 8638123 · DOI
  80. [84]Calderone A. Jover T. Mashiko T. Noh K.M. Tanaka H. Bennett M.V. Zukin R.S. Late calcium EDTA rescues hippocampal CA1 neurons from global ischemia-induced death J. Neurosci. 2004 24 9903 9913 10.1523/JNEUROSCI.1713-04.2004 15525775 PMC6730239 · DOI
  81. [85]Capasso M. Jeng J.M. Malavolta M. Mocchegiani E. Sensi SL. Zinc dyshomeostasis: A key modulator of neuronal injury J. Alzheimers Dis. 2005 8 93 108 10.3233/JAD-2005-8202 16308478 · DOI
  82. [86]Kawahara M. Kato-Negishi M. Kuroda Y. Pyruvate blocks zinc-induced neurotoxicity in immortalized hypothalamic neurons Cell. Mol. Neurobiol. 2002 22 87 93 10.1023/A:1015345813075 12064519 PMC11533741 · DOI
  83. [87]Koyama H. Konoha K. Sadakane Y. Ohkawara S. Kawahara M. Zinc neurotoxicity and the pathogenesis of vascular-type dementia: Involvement of calcium dyshomeostasis and carnosine J. Clin. Toxicol. 2011 S3 10.4172/2161-0495.S3-002 · DOI
  84. [88]Mellon P.L. Windle J.J. Goldsmith P.C. Padula C.A. Roberts J.L. Weiner R.I. Immortalization of hypothalamic GnRH neurons by genetically targeted tumorigenesis Neuron 1990 5 1 10 10.1016/0896-6273(90)90028-E 2196069 · DOI
  85. [90]Kawahara M. Konoha K. Nagata T. Sadakane Y. Protective substances against zinc-induced neuronal death after ischemia: Carnosine a target for drug of vascular type of dementia Recent Patents CNS Drug Discov. 2007 2 145 149 10.2174/157488907780832698 18221226 · DOI
  86. [93]Kawahara M. Sadakane Y. Koyama H. Konoha K. Ohkawara S. d-histidine and l-histidine attenuate zinc-induced neuronal death in GT1-7 cells Metallomics 2013 5 453 460 10.1039/c3mt20264j 23503404 · DOI
  87. [94]Mizuno D. Konoha-Mizuno D. Mori M. Sadakane Y. Koyama H. Ohkawara S. Kawahara M. Protective activity of carnosine and anserine against zinc-induced neurotoxicity: A possible treatment for vascular dementia Metallomics 2015 7 1233 1239 10.1039/C5MT00049A 25846004 · DOI
  88. [95]Tanaka K. Kawahara M. Copper enhances zinc-induced neurotoxicity and the endoplasmic reticulum stress response in a neuronal model of vascular dementia Front. Neurosci. 2017 11 58 10.3389/fnins.2017.00058 28232787 PMC5299027 · DOI
  89. [96]Tanaka K. Shimoda M. Kawahara M. Pyruvic acid prevents Cu2+/Zn2+-induced neurotoxicity by suppressing mitochondrial injury Biochem. Biophys. Res. Commun. 2018 495 1335 1341 10.1016/j.bbrc.2017.11.152 29180015 · DOI
  90. [97]Tanaka K. Shimoda M. Chuang V.T.G. Nishida K. Kawahara M. Ishida T. Otagiri M. Maruyama T. Ishima Y. Thioredoxin-albumin fusion protein prevents copper enhanced zinc-induced neurotoxicity via its antioxidative activity Int. J. Pharm. 2018 535 140 147 10.1016/j.ijpharm.2017.11.012 29122608 · DOI
  91. [98]Rajanikant G.K. Zemke D. Senut M.C. Frenkel M.B. Chen A.F. Gupta R. Majid A. Carnosine is neuroprotective against permanent focal cerebral ischemia in mice Stroke 2007 38 3023 3031 10.1161/STROKEAHA.107.488502 17916766 · DOI
  92. [99]Zhang X. Song L. Cheng X. Yang Y. Luan B. Jia L. Xu F. Zhang Z. Carnosine pretreatment protects against hypoxia-ischemia brain damage in the neonatal rat model Eur. J. Pharmacol. 2011 667 202 207 10.1016/j.ejphar.2011.06.003 21693116 · DOI
  93. [100]Davis C.K. Laud P.J. Bahor Z. Rajanikant G.K. Majid A. Systematic review and stratified meta-analysis of the efficacy of carnosine in animal models of ischemic stroke J. Cereb. Blood Flow Metab. 2016 36 1686 1694 10.1177/0271678X16658302 27401803 PMC5046161 · DOI
  94. [102]Prusiner S.B. Prion diseases and the BSE crisis Science 1997 278 245 251 10.1126/science.278.5336.245 9323196 · DOI
  95. [103]Carrell R.W. Lomas D.A. Conformational disease Lancet 1997 350 134 138 10.1016/S0140-6736(97)02073-4 9228977 · DOI
  96. [104]Jackson G.S. Murray I. Hosszu L.L. Gibbs N. Waltho J.P. Clarke A.R. Collinge J. Location and properties of metal-binding sites on the human prion protein Proc. Natl. Acad. Sci. USA 2001 98 8531 8535 10.1073/pnas.151038498 11438695 PMC37470 · DOI
  97. [105]Brown D.R. Qin K. Herms J.W. Madlung A. Manson J. Strome R. Fraser P.E. Kruck T. von Bohlen A. Schulz-Schaeffer W. The cellular prion protein binds copper in vivo Nature 1997 390 684 687 10.1038/37783 9414160 · DOI
  98. [106]Brown D.R. Brain proteins that mind metals: A neurodegenerative perspective Dalton Trans. 2009 21 4069 4076 10.1039/b822135a 19452053 · DOI
  99. [107]Schmitt-Ulms G. Ehsani S. Watts J.C. Westaway D. Wille H. Evolutionary descent of prion genes from the ZIP family of metal ion transporters PLoS ONE 2009 4 e7208 10.1371/journal.pone.0007208 19784368 PMC2745754 · DOI
  100. [108]Watt N.T. Griffiths H.H. Hooper N.M. Neuronal zinc regulation and the prion protein Prion 2013 7 203 208 10.4161/pri.24503 23764834 PMC3783104 · DOI
  101. [109]Bonetto V. Massignan T. Chiesa R. Morbin M. Mazzoleni G. Diomede L. Angeretti N. Colombo L. Forloni G. Tagliavini F. Synthetic miniprion PrP106 J. Biol. Chem. 2002 277 31327 31334 10.1074/jbc.M203275200 12058037 · DOI
  102. [110]Kang J.H. Kim K.S. Enhanced oligomerization of the alpha-synuclein mutant by the Cu, Zn-superoxide dismutase and hydrogen peroxide system Mol. Cells 2003 15 87 93 12661766
  103. [111]Villari V. Attanasio F. Micali N. Control of the structural stability of α-crystallin under thermal and chemical stress: The role of carnosine J. Phys. Chem. B 2014 118 13770 13776 10.1021/jp5092009 25356752 · DOI
  104. [112]Del Prete D. Lombino F. Liu X. D’Adamio L. APP is cleaved by Bace1 in pre-synaptic vesicles and establishes a pre-synaptic interactome, via its intracellular domain, with molecular complexes that regulate pre-synaptic vesicles functions PLoS ONE 2014 9 e108576 10.1371/journal.pone.0108576 25247712 PMC4172690 · DOI
  105. [114]Mellone M. Pelucchi S. Alberti L. Genazzani A.A. Di Luca M. Gardoni F. Zinc transporter-1: A novel NMDA receptor-binding protein at the postsynaptic density J. Neurochem. 2015 132 159 168 10.1111/jnc.12968 25319628 · DOI
  106. [115]Howells C. West A.K. Chung R.S. Neuronal growth-inhibitory factor (metallothionein-3): Evaluation of the biological function of growth-inhibitory factor in the injured and neurodegenerative brain FEBS J. 2010 277 2931 2939 10.1111/j.1742-4658.2010.07718.x 20561053 · DOI
  107. [116]Uchida Y. Takio K. Titani K. Ihara Y. Tomonaga M. The growth inhibitory factor that is deficient in the Alzheimer’s disease brain is a 68 amino acid metallothionein-like protein Neuron 1991 7 337 347 10.1016/0896-6273(91)90272-2 1873033 · DOI
  108. [117]De Marchis S. Modena C. Peretto P. Migheli A. Margolis F.L. Fasolo A. Carnosine-related dipeptides in neurons and glia Biochemistry 2000 65 824 833 10951101
  109. [118]Bakardjiev A. Carnosine and β-alanine release is stimulated by glutamatergic receptors in cultured rat oligodendrocytes Glia 1998 24 346 351 10.1002/(SICI)1098-1136(199811)24:3<346::AID-GLIA9>3.0.CO;2-# 9775986 · DOI
  110. [119]Kaneko J. Enya A. Enomoto K. Ding Q. Hisatsune T. Anserine (beta-alanyl-3-methyl-l-histidine) improves neurovascular-unit dysfunction and spatial memory in aged AβPPswe/PSEN1dE9 Alzheimer’s-model mice Sci. Rep. 2017 7 12571 10.1038/s41598-017-12785-7 28974740 PMC5626714 · DOI
  111. [120]Hisatsune T. Kaneko J. Kurashige H. Cao Y. Satsu H. Totsuka M. Katakura Y. Imabayashi E. Matsuda H. Effect of anserine/carnosine supplementation on verbal episodic memory in elderly people J. Alzheimers Dis. 2016 50 149 159 10.3233/JAD-150767 26682691 PMC4927867 · DOI
  112. [121]Tomonaga S. Hayakawa T. Yamane H. Maemura H. Sato M. Takahata Y. Morimatsu F. Furuse M. Oral administration of chicken breast extract increases brain carnosine and anserine concentrations in rats Nutr. Neurosci. 2007 10 181 186 10.1080/10284150701587338 18019400 · DOI
  113. [122]Stuerenburg H.J. The roles of carnosine in aging of skeletal muscle and in neuromuscular diseases Biochemistry 2000 65 862 865 10951106

Cited by

Sorted by citations

Authors
Kawahara, M., Tanaka, K.-I., & Kato-Negishi, M.
Affiliations
  • Musashino University (JP)
  • Department of Bio-Analytical Chemistry, Faculty of Pharmacy, Musashino University, 1-1-20 Shinmachi, Nishitokyo-shi, Tokyo 202-8585, Japan
Corresponding author
Kawahara, Masahiro
ORCID
Venue
Nutrients
Publisher
MDPI AG
Published
2018-01-29
Volume
10
Issue
2
Pages
147
ISSN
2072-6643 (ISSN-L)
DOI
10.3390/nu10020147
PMC
PMC5852723
OpenAlex
W2788938005
Cited by
134
References
5
Citations by year
2026: 11 · 2025: 12 · 2024: 18 · 2023: 18 · 2022: 19 · 2021: 18 · 2020: 17 · 2019: 14 · 2018: 6 · 2017: 1
FWCI
1.81
Type
journal article
Language
en
Open access
Licence
Locations
  • Nutrients (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Japan Society for the Promotion of Science (26460177, 18K06669)
Topics
  • Health Sciences › Medicine › Physiology › Biochemical effects in animals
  • Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
zinc, carnosine, neurodegenerative diseases, zinc homeostasis, Alzheimer's disease, prion disease, polaprezinc, neuroprotection, antioxidant activity, metal chelation, antiglycation, zinc supplementation
MeSH terms
Alzheimer Disease, Animals, Antioxidants, Brain, Carnosine, Chelating Agents, Disease Models, Animal, Homeostasis, Humans, Zinc, Dementia, Vascular, Prion Diseases, Neuroprotective Agents, Dietary Supplements, Neurodegenerative Diseases, Amyloidogenic Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review